Riesgo de reactivación de hepatitis B pasada en pacientes con psoriasis tratados con biológicos. Análisis retrospectivo de 20 casos. Registro de BIOBADADERM

Sanz-Bueno, Jimena; Vanaclocha, F.; García‐Doval, I.; Torrado, R.; Carretero, G.; Daudén, E.; Ruíz‐Genao, Diana; Alsina-Gibert, Mercè; Pérez-Zafrilla, Beatriz; Pérez-Rial, G.; Rivera, R.

doi:10.1016/j.ad.2015.01.010

Cited by 37 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are supported by a 2015 retrospective analysis by Sanz-Bueno et al, 22 which identified 20 patients who were treated for psoriasis with a biologic agent (TNF inhibitor or ustekinumab) and had evidence of prior infection with hepatitis B (defined as the presence of anti-HBc, the absence of HBsAg, and the presence or absence of anti-HBs) and assessed the cases for evidence of HBV reactivation. Hepatitis B reactivation was defined as the detection of HBV DNA in blood ± conversion to HBsAg+, and it was found that over a median 40-month follow-up there were no cases of reactivation of HBV despite none of the patients receiving chemoprophylaxis.…”

Section: Overview Of Serious Adverse Effects Of Biologicsmentioning

confidence: 83%

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Hanley

Handford

Lavery

et al. 2016

PTT

View full text Add to dashboard Cite

BackgroundCurrent treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.ObjectiveThe aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the treatment of psoriasis should be monitored for adverse events.MethodsThe MEDLINE database was searched to identity the current literature on the safety and screening guidance associated with infliximab, etanercept, adalimumab, ustekinumab, and secukinumab.LimitationsThis study was limited by the lack of data evaluating monitoring in patients with psoriasis undergoing treatment with a biologic therapy.ResultsThis review of the current literature highlights that there are areas of routine screening, which are recommended in current practice, which require further evidence to investigate its true utility.ConclusionMost screening and monitoring tests performed routinely in clinical practice are supported by minimal clinical evidence, highlighting the need for more studies to evaluate the role and value of the different modalities of screening and monitoring for adverse events in those with psoriasis receiving treatment with biologic therapies.

show abstract

Section: Overview Of Serious Adverse Effects Of Biologicsmentioning

confidence: 83%

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Hanley

Handford

Lavery

et al. 2016

PTT

View full text Add to dashboard Cite

show abstract

“…A total of 32 studies were identified evaluating immunosuppressing biologics and other disease-modifying antirheumatic drugs (DMARDs) for autoimmune diseases, which included rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and aplastic anemia (Table 4). 67-98 TNFα inhibitors were the most common agents evaluated, and 6 studies included rituximab. Use of prophylaxis was rare.…”

Section: Resultsmentioning

confidence: 99%

Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In 2015, Sanz-Bueno et al published a retrospective analysis of 20 cases from the Spanish Registry of Adverse Systemic Drug Reactions in Psoriasis (BIOBADADERM). 19 In the study were also included patients treated with ustekinumab. Out of 1,030 patients treated with biologics, the authors identified 20 anti-HBs+ and anti-HBc+ patients treated with anti-TNF-α agents and none of them had HBVr, therefore assessing the HBVr risk to be 0% in their study.…”

Section: Methodsmentioning

confidence: 99%

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management

Cannizzaro¹,

Franceschini²,

Esposito³

et al. 2017

PTT

View full text Add to dashboard Cite

The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α. Although anti-TNFs are considered moderate immunosuppressive drugs, the incidence of HBVr in psoriatic patients is lower compared to patients affected by other immune-mediated diseases treated with TNF inhibitors. HBV prophylaxis should be probably reserved to anti-HBs+/anti-HBc+ patients with a viral load <2000 IU/mL and alterations in serum liver enzymes, in order to prevent HBVr.

show abstract

Riesgo de reactivación de hepatitis B pasada en pacientes con psoriasis tratados con biológicos. Análisis retrospectivo de 20 casos. Registro de BIOBADADERM

Cited by 37 publications

References 26 publications

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management

Contact Info

Product

Resources

About